Status:

COMPLETED

The Effect of GIP(3-30)NH2

Lead Sponsor:

University Hospital, Gentofte, Copenhagen

Collaborating Sponsors:

Steno Diabetes Center Copenhagen

University of Copenhagen

Conditions:

Endocrine - Other

Eligibility:

MALE

18-70 years

Phase:

NA

Brief Summary

Infusion of glucose-dependent insulintropic polypeptide (GIP) receptor antagonist and evaluation of effect of insulin secretion in healthy subjects.

Detailed Description

Infusion of glucose-dependent insulintropic polypeptide (GIP) receptor antagonist and evaluation of effect of insulin secretion in healthy subjects. Six study hyperglycemic clamps (10 mmol/l) pr. par...

Eligibility Criteria

Inclusion

  • Healthy
  • BMI 19-28 kg/m\*m
  • Stable body weight

Exclusion

  • Diabetes
  • Anemia
  • First-degree relatives with diabetes

Key Trial Info

Start Date :

December 6 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2019

Estimated Enrollment :

8 Patients enrolled

Trial Details

Trial ID

NCT03770910

Start Date

December 6 2018

End Date

December 1 2019

Last Update

March 26 2020

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Clinical Metabolic Physiology

Gentofte Municipality, Copenhagen, Denmark, 2900

2

Clinical Metabolic Physiology

Copenhagen, Gentofte, Denmark, 2900

The Effect of GIP(3-30)NH2 | DecenTrialz